Cevian Capital disclosed a stake above 14% in Smith & Nephew in late July, marking the largest activist position the Stockholm-based firm has taken in the London-listed medical device manufacturer since initial entry. The filing arrives three quarters into a restructuring cycle that has yet to satisfy institutional holders watching orthopaedics revenue flatten against Stryker and Zimmer Biomet comps.
The stake increase follows 18 months of documented engagement between Cevian managing partners and Smith & Nephew's Remuneration Committee, during which the activist pushed for operational separation of the Advanced Wound Management segment and margin improvement targets in the Sports Medicine & ENT franchise. Smith & Nephew trades at 13.2x forward earnings, a 22% discount to the peer group median, despite holding the number-three global position in knee and hip implants by unit volume. Cevian's prior activist campaigns at Ericsson and Volvo ran an average 31 months from initial disclosure to realization event.
The timing matters for three reasons. First, Smith & Nephew enters Q3 earnings with consensus expecting 4.1% organic revenue growth, down from 5.8% in the prior-year period, as elective surgery volumes in the UK and Germany remain 7-9% below pre-pandemic run rates. Second, the company's CEO transition completed in May, installing Deepak Nath from the Zimmer Biomet playbook, which historically precedes portfolio rationalization within 6-9 months of executive onboarding. Third, Cevian's European healthcare book now concentrates 38% of disclosed AUM in two names—Smith & Nephew and a 9.7% stake in Fresenius—signaling sector-specific conviction rather than opportunistic entry.
Allocators watching medtech M&A should note that Smith & Nephew's Advanced Wound Management division, generating $1.1 billion in trailing revenue at 19% EBITDA margins, fits the profile for private equity carve-out or trade sale to J&J or 3M's separated health business. The division's dressing and negative-pressure wound therapy franchises hold the number-two and number-one global positions respectively, with limited operational synergy to the orthopaedics core. Cevian's historical playbook includes exactly this separation logic—the firm catalyzed ABB's $11 billion power grid divestiture to Hitachi in 2018 after crossing 10% ownership and securing board representation.
Market participants should track three near-term catalysts. Smith & Nephew's Q3 earnings on October 31 will clarify whether Nath's first 100 days include formal strategic review language, particularly around portfolio optimization. Cevian's 13F filing for Q3, due mid-November, will show whether the stake moved above 15%, the threshold that typically precedes public commentary or board-seat requests under UK Takeover Code provisions. Finally, orthopaedics sector M&A comps will set valuation floors—Stryker's $3.7 billion acquisition of Vocera in 2022 priced at 7.1x revenue, while Zimmer Biobet's pipeline suggests continued appetite for bolt-on deals in the $500 million to $2 billion range.
The filing arrives as European activist dry powder sits at a seven-year high of $28 billion, with healthcare and industrials representing 41% of disclosed new positions year-to-date. Cevian's move past 14% removes the ambiguity of passive observation.